Angstrom Bio
Angstrom Bio is revolutionizing diagnostics through amplicon sequencing and machine learning, aiming to improve human lives by maximizing the reach of diagnostics. Their core product, AMPD, is a population-scale NGS diagnostic platform offering cost-effective, massively-parallel viral diagnostics with unprecedented throughput, sensitivity, and scale-enabling cost. AMPD is designed for high-frequency testing of COVID-19 and other pathogens, providing accurate and affordable results with a rapid turnaround time. The company also focuses on optimizing research and therapeutics through computational methods for antibodies. Angstrom Bio is based in Austin, TX and is building a world-class team.
Angstrom Bio
Angstrom Bio is revolutionizing diagnostics through amplicon sequencing and machine learning, aiming to improve human lives by maximizing the reach of diagnostics. Their core product, AMPD, is a population-scale NGS diagnostic platform offering cost-effective, massively-parallel viral diagnostics with unprecedented throughput, sensitivity, and scale-enabling cost. AMPD is designed for high-frequency testing of COVID-19 and other pathogens, providing accurate and affordable results with a rapid turnaround time. The company also focuses on optimizing research and therapeutics through computational methods for antibodies. Angstrom Bio is based in Austin, TX and is building a world-class team.
TL;DR
Founded: 2019
Headquarters: Austin, Texas
Core product: AMPD — nanopore sequencing + machine-learning platform for high-throughput respiratory pathogen diagnostics
Latest disclosed funding: Seed, $3,000,000 (Jun 16, 2021) led by GreyBird Ventures
Employee count (reported): 4
Company Overview
Problem Domain
Population-scale molecular diagnostics and computational optimization for research and therapeutics
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
3000000
Announced $3 million investment; GreyBird partners joined the board
Investor Signal
“Lead investor GreyBird Ventures participated in Seed and joined board representation”